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Abstract 
Background: Typhoid fever is a global health problem. The World Health Organization (WHO) estimates that the current annual global 
burden of typhoid is approximately 22 million new cases, 5% of which are fatal.  
Methodology: To assess the trends in antibiotic resistance in 100 Salmonella enterica serovar Typhi strains were isolated from the blood of 
patients in Nairobi, Kenya, from 2004 to 2006. All isolates were tested against ampicilin, chloramphenic, nalidixic acid, ciprofloxacin, 
cotrimoxazole, cefuroxime, cefriaxone, amoxycillin/clavulanic acid, tetracycline and gentamycin. Susceptibility and resistance were 
determined using MIC and disk diffusion tests. 
Results: From 2004 to 2006 a total of 100 strains were studied; 70% of the isolates were multidrug resistant (MDR) while 15% of the isolates 
were sensitive to all drugs tested. Of 13 isolates that were resistant to ciprofloxacin and nalidixic acid by disk diffusion, 11 had an MIC of 0. 
25 µg/ml while two isolates had an MIC of 1.00 µg,/ml. Resistance in ampicillin decreased from  88% in 2004 to 64% in 2005; this increased 
to 76% in 2006. Similar trends were observed for four other antibiotics tested. 
Conclusion: The prescription of first-line antibiotics used in the treatment of S. Typhi should be stopped temporarily. Drugs such as 
cipfloxacin would be useful in the treatment of typhoid caused by MDR S. Typhi. There is need to monitor the resistance in flouroquinolones 
as resistance to these drugs has been observed and they are the current drugs used to treat typhoid.   
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Introduction 
Typhoid fever is a global health problem [1]. The 
World Health Organization (WHO) estimates that the 
current annual global burden of typhoid is 
approximately 22 million new cases, 5% of which are 
fatal
 
[2,3]. Typhoid fever is endemic in most parts of 
Central America, and large epidemics occur in many 
parts of Southeast Asia, including India, Pakistan, 
Bangladesh, Vietnam, Malaysia, Indonesia, China 
and Tajikistan
 
[4].  Clinically apparent bacteraemic S. 
Typhi infection in children aged less than three years 
has been described in Bangladesh, India, Jordan, and 
Nigeria
 
[5]. 
Since 1997 increasing numbers of multidrug-
resistant (MDR) S. Typhi have been isolated from 
patients in outbreaks in Nairobi and Embu, Kenya, 
which were related to damaged water supply systems
 
[6].  From these outbreaks MDR S. Typhi were 
sensitive to nalidixic acid and ciprofloxacin but the 
minimum inhibition concentrations (MICs) were ten 
times higher than for the non-MDR strains.  
The antibiotics that form the mainstay of therapy 
for typhioid patients in developing countries are 
ampicilin, co-trimoxazole and chloramphenicol. Due 
to the increasing resistance to antibacterials used 
traditionally for therapy, the use of fluoroquinolones, 
such as ciprofloxacin and ofloxacin, for the treatment 
of typhoid has become more common in the Asian 
countries. This in turn has led to an increase in 
fluoroquinolone resistance in S.  Typhi [9].  
Sporadic cases of ciprofloxacin treatment failure 
in typhoid fever have been reported in Europe and 
more recently, in Asia [10,11]. Njinkeng et al. (2005) 
report that MDR S. Typhi and nalidixic acid resistant 
S. Typhi (NARST) strains were found in Cameroon, 
Central Africa. NARST have also been reported in 
East Africa [8]. The aim of this study was to 
characterize S. Typhi using antibiotic susceptibility  
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patterns. The S. Typhi studied was isolated from 
patients presenting to the Aga Khan University and 
the Kenyatta National Hospitals in Nairobi Kenya, 
suspected to have typhoid fever.  
 
Materials and methods 
Study Design 
A descriptive, cross-sectional study design was used. 
 
Setting 
Isolates of S. Typhi were obtained from stock 
cultures at the Center for Microbiology Research at 
KEMRI, Nairobi.  The isolates had originated from 
blood cultures of patients with suspected cases of 
typhoid fever who had presented themselves to the 
Aga Khan University Hospital and the Kenyatta 
National Hospital in Nairobi, Kenya. 
 
Bacterial strains 
One hundred S. Typhi isolates were obtained 
from blood cultures of patients with suspected cases 
of typhoid fever who had presented themselves to the 
Aga Khan University Hospital and the Kenyatta 
National Hospital in Nairobi, Kenya. Bacterial strains 
had been isolated between 2004 and 2006. 
 
Antibiotic susceptibility testing 
Antimicrobial susceptibility testing was 
performed using a disc diffusion method according to 
CLSI guidelines (CLSI, 2005). Escherichia coli 
ATCC 25922
® 
(with known disc zones and MICs) 
was used as a control for growth and potency of 
antibiotics. The antibiotic discs, (all from Himedia, 
Maharashtra, India) contained ampicillin (30 µg), 
tetracycline
 
(30 µg), cotrimoxazole (1:25 µg), 
chloramphenicol
 
(30 µg), gentamicin (10 µg),
 
amoxycillin/clavulanic acid (30µg), ciprofloxacin (5 
µg), cefuroxime
 
(30 µg), ceftriaxone (30 µg), and 
nalidixic acid
 
(30 µg) from Becton Dickinson, San 
Jose, California, USA. The zones of inhibition were 
measured in millimeters (mm) and recorded.  
 
Minimum inhibitory concentration 
S. Typhi isolates that were resistant to nalidixic 
acid and ciprofloxacin by disc diffusion test had MIC 
performed for using an automated Vitek 2 compact 
system (bioMérieux, Inc., Durham NC, USA). 
 
Results 
A total of 70 isolates were MDR (resistant to 
ampicillin, cotrimoxazole and chloramphenicol) 
while 15 isolates were sensitive to all drugs tested.  
Only one isolate was resistant to tetracycline alone 
while four isolates were multiply resistant to two 
drugs each, which included ampicillin, 
chloramphenicol, amoxycillin/clavulanic acid and 
tetracycline.  Five isolates were resistant to five 
drugs, which included tetracycline, ampicillin, 
cotrimoxazole, chloramphenicol, and nalidixic acid.  
The most effective drugs were gentamicin, with 99 
isolates being susceptible to the drug; this was 
followed by ceftriaxone in which 94 isolates were 
susceptible to the drug. Of the 100 isolates, 82 were 
sensitive to ciprofloxacin, 78 isolates were sensitive 
to cefuroxime, and 65 isolates were sensitive to 
nalidixic acid. The least effective drugs included 
tetracycline and ampicillin (only 24 isolates were 
sensitive to both drugs).  
Resistance to individual antibiotics varied 
slightly during the study period. For instance, the 
prevalence of chloramphenical-resistant isolates, 
which was 81% in 2004, reduced gradually to 67% 
by 2005 and slightly increased to 76% in 2006. 
Similar trends were observed in ciprofloxacin, 
ampicillin, tetracycline, cotrimoxazole, nalidixic acid 
and ciprofloxacin. There was a gradual decrease in 
resistance in Augmentin observed over the study 
period.  
The highest number of MDR S. Typhi was 
recorded in 2004, when 73% of the organisms 
isolated were MDR. There was no significant 
increase in MDR from 2005 (68%) to 2006 (69%) 
(Table 1). 
Thirteen S. Typhi isolates that were resistant to 
ciprofloxacin and nalidixic acid by disk diffusion 
technique had MIC tests performed on them. The 
MICs of the 13 isolates ranged from 0.25 to 1.00 
µg/ml.  Eleven S. Typhi had an MIC of 0. 25 µg/ml 
while two isolates had an MIC of 1 .00 µg/ml.  
 
Discussion 
Typhoid fever continues to pose a public health 
challenge in developing countries and the World 
Health Organization (WHO) estimates that the 
current annual global burden of typhoid is 
approximately 22 million new cases, 5% of which are 
fatal [2,3].  There has been an increasing concern 
about the prevalence of MDR S. Typhi strains in 
developing countries; several reports showing that 
MDR S. Typhi with plasmid-mediated resistance to 
conventional antibiotics including chloramphenicol, 
ampicillin, and contrimoxazole, abound in different 
parts of the developing world including Kenya [7]. 
This study examined a total of 70 MDR isolates of S.  
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Typhi isolated from the Aga Khan University 
Hospital and the Kenyatta National Hospital. 
Previous studies have shown that the prevalence of 
MDR S. Typhi has been rising steadily from 50 to 
65% in 1997 to 1999 [7] to the present level of 70% 
in this study. The rise in MDR could be attributed to 
an increase in misuse of drugs that are commonly 
available to the public for treatment of infections. 
Threlfall et al. (2001) established that in Britain, the 
increase in MDR to chloramphenicol, ampicillin, and 
trimethoprim increased from 21% in 1991 to 36% in 
1994.  The increasing levels of resistance were also 
reported by Kariuki et al. (2000) who established that 
from 1988 to 1993, all the S. Typhi isolated from 
Kenya were fully sensitive to all drugs used, which 
was in contrast to 82% of S. Typhi isolated in 1997 to 
1999 which were resistant to ampicillin, tetracycline 
and chloramphenicol. 
The emergence of MDR S. Typhi in Kenya is of 
concern because it limits the number of first-line 
antibiotics that are commonly used for treating 
typhoid as well other bacterial infections in hospitals.  
This poses a major challenge to health care.  
Currently, due to the increase of MDR strains in 
many parts of the world, the drugs of choice for 
treatment of S. Typhi are fluroquinolones.  However, 
sporadic cases of ciprofloxacin treatment failure in 
typhoid fever have been reported in Europe and more 
recently, in Asia [10,11]. Resistance to nalidixic acid 
has also been reported in Cameroon where there has 
been a treatment failure to fluoroquinolones [12]. 
In this study, S. Typhi that were resistant to 
nalidixic acid were reported. Resistance in nalidixic 
acid was 31% in 2004 and increased to 38% in 2005. 
Although ciprofloxacin is recommended as the drug 
of choice for treatment of MDR S. Typhi infections 
[13], a study by
 
the National Institute of Health of 
Korea (NIHK) suggested that the clinical failure of 
empirical fluoroquinolone treatment might occur as 
the nalidixic acid resistance rate had rapidly 
increased from 3.5% in 2001 to 23.3% in 2002 in  
 
 
 
Korea [14].  In the present study, 18% of the 
organisms were resistant to ciprofloxacin and 15% 
were recorded as intermediate by disk diffusion 
technique.   
In conclusion, the high levels of resistance to 
commonly available antibiotics including 
fluroquinolones is of major public health concern in 
the treatment of typhoid fever and other bacterial 
infections in Kenya. To minimize the emergence and 
spread of resistance we recommend a prudent 
approach to the availability and usage of antibiotics 
in Kenya so that only qualified trained and medical 
personnel should administer antibiotics to patients. 
Also, the drug resistance in S. Typhi should be 
continuously monitored in Kenya to determine the 
extent of resistance to currently used drugs in the 
treatment of typhoid. There is also need to improve 
laboratory capacity detection and surveillance of 
typhoid. Despite improvements in health care 
facilities in Kenya, many areas still lack proper 
sanitation and good quality drinking water, which 
contributes to increased risk of transmission of all 
enteric pathogens.  To minimize the emergence and 
spread of resistance we recommend a prudent 
approach to the availability and usage of antibiotics. 
Tools that are more specific and sensitive such as 
PCR should be adopted to improve surveillance for 
resistant strains of S. Typhi. 
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